Epigenetics (“Epi”; “over “ or “above” genetics) is recognized as those systems that control the expression of DNA-coded genes, but do not reside in the base pair sequences of the DNA. Rather, these control mechanisms are based on factors or molecules that bind to specific regions of the DNA (the genome), affecting gene expression. The three most important, and best understood mechanisms, are:
This report an assessment of commercial outlook for each one of these categories. It includes market size and forecast for epigenetics in pharmaceutical and diagnostic applications. Epigenetics constitutes a challenge to the long held paradigm of DNA base pair sequences as the prime determinant of the phenotype. Because of this profound intellectual shift, a vast new area of biological investigation is rapidly unfolding. This presents significant opportunities for understanding disease processes and developing the means of combating them.
The examination of many diseases in a completely new light means there exist a wealth of opportunities to develop new diagnostic and therapeutic approaches. At the same time it means that outdated concepts will have to be revised. This report looks at the science behind epigenetics and deals with opportunities for product development based on epigenetic technologies and the outlook for the future in this exciting area of pharmaceutical technologies. In doing so, the report provides:
The report strives to predict the potential for epigenomics while reminding market-watchers of the challenges and possible limiting factors in this market.
Mabs" and molecular tests are among the growth industries of pharmaceuticals and diagnostics, but they may have competition long-term from an unexpected source.
Epigenetics is a potential game-changer in the clinical therapeutics market and significant in testing as well. It refers to technologies involving changes in genetic material that find their origins in causes other than base pairs alterations in the DNA of the host. Examples of such changes include DNA methylation and histone acetylation, both of which have been known for many years to cause changes in gene expression. This report Epigenetics, Present and Future Applications for Pharmaceuticals and Diagnostics describes the progress that has been made in our understanding of the basic science of epigenomics and considers the practical accomplishments being reported by the private sector.
The study of epigenomics today finds itself at a tuningpoint, with many unanswered questions and a proliferation of opportunities forproducts based on the constant flow of new research findings. This report is essential for pharmaceutical and diagnostic marketers looking to develop future business plans and determine opportunities in a promising field.
Related Reports:Biomarker-Based Tests: Faster Revenue Growth
Feb 26, 2016 - KLI5912540 - $0.00
Growth Potential of Specific Biomarker-Based Tests: White Paper
Feb 9, 2016 - KLI5878138 - $0.00
The Global Market for Biomarkers (Cancer Markers, Cardiac Markers, Immunological Disease Markers, Infectious Disease Markers, Others)
Dec 10, 2015 - KLI5789361 - $4,200.00
The World Market for Cancer Therapeutics (Monoclonal Antibodies, TKIs, Vaccines, Cytokines, Gene Therapy, Chemotherapy, Others), Phase I- III Pipeline Analysis, Markets by Segment
Nov 12, 2015 - KLI5752001 - $4,200.00
Biotechnology Companies in Emerging Markets (China, Singapore, Brazil, South Africa, South Korea, Turkey, India, Russia)
Aug 17, 2015 - KLI5668767 - $750.00
Proteomics Markets for Clinical IVD Applications and Research Applications (Mass Spectrometry, Chromatography, Microarrays, Electrophoresis, Immunoassays, Other Technologies)
Sep 4, 2014 - KLI5321482 - $4,200.00
miRNA Research and Diagnostics Markets
Sep 4, 2014 - KLI5332151 - $995.00
Physician Office Laboratory (POL) Markets, 3rd Edition (Markets for Office-Based Chemistry, Glucose, Coagulation PT, Autoimmune, HIV, Hep, Cardiac Markers, PSA, Flu, HbA1c, Hematology, FOB and Other Tests)
Aug 15, 2014 - KLI5314670 - $3,995.00
Companion Diagnostics Markets (Cancer, Cardiovascular and Blood, Metabolic, Infection, Neurological, Others)
Aug 8, 2014 - KLI5310061 - $3,995.00
Biotech Funding Deals and Partnerships: Analysis of Recent Venture Capital and Corporate Capital Funding and Other Transactions
May 20, 2014 - KLI5248409 - $3,500.00
Questions?Contact a research specialist >
Live Chat Software
Most Popular ResearchRetail Clinics 2015: Growth of Stores, Consumer Opinion, Leading Competitors, Sales of Products to Clinics (Diagnostic Tests, Pharmaceuticals, Vaccines), Clinic Sales Forecasts and Trends World Market for Prescription Dermatological Drugs, 9th Edition (Anti-acne, Anti-aging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer, Melasma and Seborrhea Treatments) The World Market for Clinical Nutrition Products (Infant, Parenteral and Enteral Foods), 6th Edition Healthcare Associated Infection (HAI) Control Markets: Disinfection, Area, Sterilization, Device Sterilization, Testing-C.diff, Testing-MRSA, Treatments The World Market for Cancer Therapeutics (Monoclonal Antibodies, TKIs, Vaccines, Cytokines, Gene Therapy, Chemotherapy, Others), Phase I- III Pipeline Analysis, Markets by Segment Out-of-Pocket Healthcare Expenditures in the United States